Skip to main content
Zosia Chustecka on Muck Rack

Zosia Chustecka

Verified
London
As seen in: Medscape, WebMD, MedicineNet, Internal Medicine News, JCOM | Journal of Clinical Outcomes Management, MDEdge, MDedge Dermatology, MDedge Hematology and Oncology, Univadis ES
News Editor of Medscape Oncology, award-winning medical journalist, writing and editing news articles about cancer on a daily basis
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zosia

Contact Zosia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA approves glofitamab for DLBCL

|
By Oncology Zosia Chustecka, Zosia Chustecka Verified
| MDedge Hematology and Oncology Verified
The Food and Drug Administration has granted accelerated approval for glofitamab (Columvi) for use in certain types of lymphoma. The indication is for use in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or with LBCL arising from follicular lymphoma who have received two or more lines of systemic therapy.
Open in Who Shared Issue with article?

FDA approves glofitamab for DLBCL

|
By Zosia Chustecka Verified
| MDEdge Verified
The Food and Drug Administration has granted accelerated approval for glofitamab (Columvi) for use in certain types of lymphoma. The indication is for use in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or with LBCL arising from follicular lymphoma who have received two or more lines of systemic therapy.
Open in Who Shared Issue with article?

Two ICIs Upfront for Advanced Melanoma

|
By Grant McArthur Verified, M. Alexander Otto Verified, Zosia Chustecka Verified
| Medscape Verified
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel Immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced melanoma, allowing some patients who respond to live for years. But there is still debate about how to best use these agents.
Open in Who Shared Issue with article?
See all 138 articles